EMA Expired: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA has expired the marketing authorization for Blenrep (belantamab mafodotin) held by GlaxoSmithKline Trading Services Limited, with the decision dated 23 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Status: Expired. Therapeutic area: Multiple Myeloma. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 23/02/2024. Conditional approval. Orphan medicine